Efficacy of Pimozide Augmentation for Clozapine Partial Response
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This is a 12 week outpatient study for patients with schizophrenia who are on Clozapine, but continue to experience symptoms. The purpose of this project is to find out if small doses of pimozide (an antipsychotic medication, taken by mouth) will be helpful in reducing symptoms (such as hearing voices, having trouble in organizing your thoughts, lack of interest in life events and social activities), compared to placebo (an inactive substance, "sugar pill"), when added to clozapine in patients with schizophrenia.
The participant will be asked to come in once a week to meet with the research staff and study doctor. The participant will continue to see your regular clinician during this study for all normal appointments. The participant will remain on your current medications throughout the study. During the study you will be randomly selected to be put on a small dose of Pimozide or placebo.
| Condition | Intervention | Phase |
|---|---|---|
|
Schizophrenia |
Drug: Pimozide Drug: placebo |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Efficacy of Pimozide Augmentation for Clozapine Partial Response |
- Brief Psychiatric Rating Scale (BPRS) [ Time Frame: baseline and monthly ] [ Designated as safety issue: No ]
- Scale for the Assessment of Negative Symptoms (SANS) [ Time Frame: baseline and monthly ] [ Designated as safety issue: No ]
- Clinical Global Impression (CGI) [ Time Frame: Baseline and monthly ] [ Designated as safety issue: No ]
- Brief neurocognitive battery [ Time Frame: Baseline and monthly ] [ Designated as safety issue: No ]
- QTC changes [ Time Frame: Baseline and weekly ] [ Designated as safety issue: Yes ]
| Enrollment: | 29 |
| Study Start Date: | January 2004 |
| Study Completion Date: | June 2011 |
| Primary Completion Date: | June 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Placebo Comparator: 1
placebo pimozide
|
Drug: placebo
half of the subjects are randomized to placebo
|
|
Active Comparator: 2
active pimozide
|
Drug: Pimozide
half of the subjects are randomized to the active drug
|
Detailed Description:
If you choose to participate, you will first have screening tests to find out if you are eligible. The study physician will do a number of tests including a physical examination, a routine medical history, lab tests for blood and urine, and EKG (to monitor your heart) and interviews about your physical and mental health.
At each visit you will complete an EKG (to monitor your heart), vital signs, and discuss how you are feeling with the research staff and doctor. Once a month, we will also conduct a slightly longer interview with you about your symptoms and draw one tube of blood to check your Clozapine level. At the beginning and end of the study, you will do some pencil and paper games called "Neurocognitive tests".
If you are interested in participating in this study, we will go over it in greater detail with you, including the possible benefits and risks associated with participating. We will make sure you understand the study before you begin. This study is completely voluntary, which means that you can choose to stop participating in the study at any time.
Eligibility| Ages Eligible for Study: | 18 Years to 60 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Diagnosis of schizophrenia or schizoaffective disorder.
- A minimum Brief Psychiatric Rating Scale (BPRS) score of 35 and a BPRS psychotic symptom cluster score of at least 8.
- Currently taking clozapine with a blood level between 350-1000 ng/ml and on a stable dose of clozapine for the past 2 weeks.
- Able to give informed consent.
Exclusion Criteria:
- A history of significant medical/neurological disease such as thyroid, renal, hepatic abnormality, seizure disorder.
- History of Neuroleptic Malignant Syndrome.
- Current substance abuse determined by urine toxicology.
- Cardiac arrhythmia, sinus bradycardia (heart rate less than 60/min), sinus tachycardia (heart rate greater than 110/min), supraventricular tachycardia, ventricular tachycardia, Wolff-Parkinson-White Syndrome, first, second, third degree atrioventricular (AV) block, atrial fibrillation, atrial flutter and junctional complexes. in baseline electrocardiogram (EKG). Study doctors will examine the EKGs and consult with an internist/cardiologist as needed.
- on EKG: QTc > 450 ms.
- Current use of macrolide antibiotics (e.g., erythromycin, clarithromycin), azole antifungal agents (e.g., ketoconazole, itraconazole), protease inhibitors (e.g., ritonavir, indinavir), nefazodone, and other medications that are associated with prolonged QTc.
- Current use of antipsychotics other than clozapine.
- Current use of sertraline.
- IQ level below 70.
- At high risk for suicidal/homicidal behavior.
- Pregnancy, lack of birth control for females of childbearing age (female patients must report use of effective method for birth control such as birth control pills, condoms, barrier methods, abstinence or have written statement from their doctors that they are medically sterile).
- Non-English speaking.
Contacts and Locations| United States, Connecticut | |
| Connecticut Mental Health Center | |
| New Haven, Connecticut, United States, 06508 | |
| VA Connecticut Healthcare System | |
| West Haven, Connecticut, United States, 06516 | |
| Principal Investigator: | Handan Gunduz-Bruce, MD | Yale University School of Medicine, Dept of Psychiatry |
More Information
No publications provided
| Responsible Party: | Handan Gunduz-Bruce, Assistant Clinical Professor, Yale University |
| ClinicalTrials.gov Identifier: | NCT00374244 History of Changes |
| Other Study ID Numbers: | 02T-251 |
| Study First Received: | September 7, 2006 |
| Last Updated: | April 26, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Yale University:
|
schizophrenia pimozide clozapine |
Additional relevant MeSH terms:
|
Schizophrenia Schizophrenia and Disorders with Psychotic Features Mental Disorders Clozapine Pimozide Serotonin Antagonists Serotonin Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Physiological Effects of Drugs |
Antipsychotic Agents Tranquilizing Agents Central Nervous System Depressants Central Nervous System Agents Therapeutic Uses Psychotropic Drugs GABA Antagonists GABA Agents Dopamine Antagonists Dopamine Agents Anti-Dyskinesia Agents |
ClinicalTrials.gov processed this record on June 17, 2013